CN115490642A - 一种含醚键的二芳基嘧啶类化合物及其制备方法与应用 - Google Patents
一种含醚键的二芳基嘧啶类化合物及其制备方法与应用 Download PDFInfo
- Publication number
- CN115490642A CN115490642A CN202211149680.4A CN202211149680A CN115490642A CN 115490642 A CN115490642 A CN 115490642A CN 202211149680 A CN202211149680 A CN 202211149680A CN 115490642 A CN115490642 A CN 115490642A
- Authority
- CN
- China
- Prior art keywords
- substituted
- unsubstituted
- amino
- pyrimidine
- dmso
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- -1 Diaryl pyrimidine compound Chemical class 0.000 title claims abstract description 38
- 238000002360 preparation method Methods 0.000 title claims abstract description 29
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 title claims abstract description 20
- 150000001875 compounds Chemical class 0.000 claims abstract description 33
- 239000003814 drug Substances 0.000 claims abstract description 11
- 241000725303 Human immunodeficiency virus Species 0.000 claims abstract description 5
- 238000006243 chemical reaction Methods 0.000 claims description 22
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 21
- 238000002844 melting Methods 0.000 claims description 19
- 230000008018 melting Effects 0.000 claims description 19
- 238000000034 method Methods 0.000 claims description 17
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical class CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 15
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 12
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 claims description 12
- 125000000623 heterocyclic group Chemical group 0.000 claims description 11
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical class [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 claims description 9
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical class [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 claims description 9
- 150000002989 phenols Chemical class 0.000 claims description 8
- 150000003839 salts Chemical class 0.000 claims description 7
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 claims description 6
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 claims description 6
- 239000002904 solvent Substances 0.000 claims description 6
- 125000001424 substituent group Chemical group 0.000 claims description 6
- YBAZINRZQSAIAY-UHFFFAOYSA-N 4-aminobenzonitrile Chemical compound NC1=CC=C(C#N)C=C1 YBAZINRZQSAIAY-UHFFFAOYSA-N 0.000 claims description 5
- PHSPJQZRQAJPPF-UHFFFAOYSA-N N-alpha-Methylhistamine Chemical compound CNCCC1=CN=CN1 PHSPJQZRQAJPPF-UHFFFAOYSA-N 0.000 claims description 5
- 239000012279 sodium borohydride Substances 0.000 claims description 5
- 229910000033 sodium borohydride Inorganic materials 0.000 claims description 5
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims description 4
- 150000001555 benzenes Chemical group 0.000 claims description 4
- 239000003153 chemical reaction reagent Substances 0.000 claims description 4
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 4
- 229910052736 halogen Inorganic materials 0.000 claims description 4
- 150000002367 halogens Chemical class 0.000 claims description 4
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 4
- UYHSQVMHSFXUOA-UHFFFAOYSA-N 2-methylthiouracil Chemical compound CSC1=NC=CC(O)=N1 UYHSQVMHSFXUOA-UHFFFAOYSA-N 0.000 claims description 3
- 125000005605 benzo group Chemical group 0.000 claims description 3
- 229910000027 potassium carbonate Inorganic materials 0.000 claims description 3
- 239000002994 raw material Substances 0.000 claims description 3
- RGHHSNMVTDWUBI-UHFFFAOYSA-N 4-hydroxybenzaldehyde Chemical class OC1=CC=C(C=O)C=C1 RGHHSNMVTDWUBI-UHFFFAOYSA-N 0.000 claims description 2
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical group C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 2
- 150000004806 hydroxypyridines Chemical class 0.000 claims description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 2
- 125000001624 naphthyl group Chemical group 0.000 claims description 2
- 238000010534 nucleophilic substitution reaction Methods 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 238000006722 reduction reaction Methods 0.000 claims description 2
- 238000006467 substitution reaction Methods 0.000 claims description 2
- HIXDQWDOVZUNNA-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-hydroxy-7-methoxychromen-4-one Chemical compound C=1C(OC)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=C(OC)C(OC)=C1 HIXDQWDOVZUNNA-UHFFFAOYSA-N 0.000 claims 4
- 230000002265 prevention Effects 0.000 claims 1
- 229940079593 drug Drugs 0.000 abstract description 7
- 239000000203 mixture Substances 0.000 abstract description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 94
- 238000005481 NMR spectroscopy Methods 0.000 description 37
- NQDJXKOVJZTUJA-UHFFFAOYSA-N nevirapine Chemical compound C12=NC=CC=C2C(=O)NC=2C(C)=CC=NC=2N1C1CC1 NQDJXKOVJZTUJA-UHFFFAOYSA-N 0.000 description 23
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 22
- 239000007787 solid Substances 0.000 description 21
- 230000003595 spectral effect Effects 0.000 description 20
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 17
- 239000000243 solution Substances 0.000 description 17
- 230000000694 effects Effects 0.000 description 15
- 210000004027 cell Anatomy 0.000 description 12
- 230000003013 cytotoxicity Effects 0.000 description 11
- 231100000135 cytotoxicity Toxicity 0.000 description 11
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 9
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 8
- 229960000689 nevirapine Drugs 0.000 description 8
- 238000001514 detection method Methods 0.000 description 7
- 239000003112 inhibitor Substances 0.000 description 7
- 229960002049 etravirine Drugs 0.000 description 6
- PYGWGZALEOIKDF-UHFFFAOYSA-N etravirine Chemical compound CC1=CC(C#N)=CC(C)=C1OC1=NC(NC=2C=CC(=CC=2)C#N)=NC(N)=C1Br PYGWGZALEOIKDF-UHFFFAOYSA-N 0.000 description 6
- 229960002555 zidovudine Drugs 0.000 description 6
- HBOMLICNUCNMMY-XLPZGREQSA-N zidovudine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](N=[N+]=[N-])C1 HBOMLICNUCNMMY-XLPZGREQSA-N 0.000 description 6
- XPOQHMRABVBWPR-UHFFFAOYSA-N Efavirenz Natural products O1C(=O)NC2=CC=C(Cl)C=C2C1(C(F)(F)F)C#CC1CC1 XPOQHMRABVBWPR-UHFFFAOYSA-N 0.000 description 5
- 229960003804 efavirenz Drugs 0.000 description 5
- XPOQHMRABVBWPR-ZDUSSCGKSA-N efavirenz Chemical compound C([C@]1(C2=CC(Cl)=CC=C2NC(=O)O1)C(F)(F)F)#CC1CC1 XPOQHMRABVBWPR-ZDUSSCGKSA-N 0.000 description 5
- VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 5
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 5
- 208000031886 HIV Infections Diseases 0.000 description 4
- 229940122313 Nucleoside reverse transcriptase inhibitor Drugs 0.000 description 4
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 4
- 238000003818 flash chromatography Methods 0.000 description 4
- 239000012074 organic phase Substances 0.000 description 4
- 239000003419 rna directed dna polymerase inhibitor Substances 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 208000030507 AIDS Diseases 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 239000002259 anti human immunodeficiency virus agent Substances 0.000 description 3
- JFDZBHWFFUWGJE-UHFFFAOYSA-N benzonitrile Chemical compound N#CC1=CC=CC=C1 JFDZBHWFFUWGJE-UHFFFAOYSA-N 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 239000012065 filter cake Substances 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 230000002209 hydrophobic effect Effects 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 229940083082 pyrimidine derivative acting on arteriolar smooth muscle Drugs 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 238000012827 research and development Methods 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- OKVJCVWFVRATSG-UHFFFAOYSA-N 3-hydroxybenzyl alcohol Chemical compound OCC1=CC=CC(O)=C1 OKVJCVWFVRATSG-UHFFFAOYSA-N 0.000 description 2
- ASHGTJPOSUFTGB-UHFFFAOYSA-N 3-methoxyphenol Chemical compound COC1=CC=CC(O)=C1 ASHGTJPOSUFTGB-UHFFFAOYSA-N 0.000 description 2
- GRFNBEZIAWKNCO-UHFFFAOYSA-N 3-pyridinol Chemical compound OC1=CC=CN=C1 GRFNBEZIAWKNCO-UHFFFAOYSA-N 0.000 description 2
- UYGBSRJODQHNLQ-UHFFFAOYSA-N 4-hydroxy-3,5-dimethylbenzaldehyde Chemical compound CC1=CC(C=O)=CC(C)=C1O UYGBSRJODQHNLQ-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 2
- 206010059866 Drug resistance Diseases 0.000 description 2
- 208000037357 HIV infectious disease Diseases 0.000 description 2
- 241000713340 Human immunodeficiency virus 2 Species 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- 125000000539 amino acid group Chemical group 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 230000036436 anti-hiv Effects 0.000 description 2
- 230000000840 anti-viral effect Effects 0.000 description 2
- 230000003197 catalytic effect Effects 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 230000030833 cell death Effects 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- LHGVFZTZFXWLCP-UHFFFAOYSA-N guaiacol Chemical compound COC1=CC=CC=C1O LHGVFZTZFXWLCP-UHFFFAOYSA-N 0.000 description 2
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 150000002611 lead compounds Chemical class 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- BVJSUAQZOZWCKN-UHFFFAOYSA-N p-hydroxybenzyl alcohol Chemical compound OCC1=CC=C(O)C=C1 BVJSUAQZOZWCKN-UHFFFAOYSA-N 0.000 description 2
- NWVVVBRKAWDGAB-UHFFFAOYSA-N p-methoxyphenol Chemical compound COC1=CC=C(O)C=C1 NWVVVBRKAWDGAB-UHFFFAOYSA-N 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 229960002814 rilpivirine Drugs 0.000 description 2
- YIBOMRUWOWDFLG-ONEGZZNKSA-N rilpivirine Chemical compound CC1=CC(\C=C\C#N)=CC(C)=C1NC1=CC=NC(NC=2C=CC(=CC=2)C#N)=N1 YIBOMRUWOWDFLG-ONEGZZNKSA-N 0.000 description 2
- 239000012266 salt solution Substances 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 238000009210 therapy by ultrasound Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- MPDDTAJMJCESGV-CTUHWIOQSA-M (3r,5r)-7-[2-(4-fluorophenyl)-5-[methyl-[(1r)-1-phenylethyl]carbamoyl]-4-propan-2-ylpyrazol-3-yl]-3,5-dihydroxyheptanoate Chemical compound C1([C@@H](C)N(C)C(=O)C2=NN(C(CC[C@@H](O)C[C@@H](O)CC([O-])=O)=C2C(C)C)C=2C=CC(F)=CC=2)=CC=CC=C1 MPDDTAJMJCESGV-CTUHWIOQSA-M 0.000 description 1
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- CHZCERSEMVWNHL-UHFFFAOYSA-N 2-hydroxybenzonitrile Chemical compound OC1=CC=CC=C1C#N CHZCERSEMVWNHL-UHFFFAOYSA-N 0.000 description 1
- SGHBRHKBCLLVCI-UHFFFAOYSA-N 3-hydroxybenzonitrile Chemical compound OC1=CC=CC(C#N)=C1 SGHBRHKBCLLVCI-UHFFFAOYSA-N 0.000 description 1
- XTVFTOVNAKNVQK-UHFFFAOYSA-N 3-hydroxypyridine-2-carbonitrile Chemical compound OC1=CC=CN=C1C#N XTVFTOVNAKNVQK-UHFFFAOYSA-N 0.000 description 1
- OYRBTWZHHRIERU-UHFFFAOYSA-N 4-[[4-(4-formyl-2,6-dimethylphenoxy)pyrimidin-2-yl]amino]benzonitrile Chemical compound CC1=CC(C=O)=CC(C)=C1OC1=CC=NC(NC=2C=CC(=CC=2)C#N)=N1 OYRBTWZHHRIERU-UHFFFAOYSA-N 0.000 description 1
- ZOFCAKIEQOGQQT-UHFFFAOYSA-N 4-[[4-[4-(hydroxymethyl)-2,6-dimethylphenoxy]pyrimidin-2-yl]amino]benzonitrile Chemical compound CC1=CC(CO)=CC(C)=C1OC1=CC=NC(NC=2C=CC(=CC=2)C#N)=N1 ZOFCAKIEQOGQQT-UHFFFAOYSA-N 0.000 description 1
- CVNOWLNNPYYEOH-UHFFFAOYSA-N 4-cyanophenol Chemical compound OC1=CC=C(C#N)C=C1 CVNOWLNNPYYEOH-UHFFFAOYSA-N 0.000 description 1
- BTJIUGUIPKRLHP-UHFFFAOYSA-N 4-nitrophenol Chemical compound OC1=CC=C([N+]([O-])=O)C=C1 BTJIUGUIPKRLHP-UHFFFAOYSA-N 0.000 description 1
- KAXIYYPIORYZLB-UHFFFAOYSA-N 5-hydroxypyridine-3-carbonitrile Chemical compound OC1=CN=CC(C#N)=C1 KAXIYYPIORYZLB-UHFFFAOYSA-N 0.000 description 1
- HTRLNWYWOKWCLV-UHFFFAOYSA-N 6-fluoropyridin-3-ol Chemical compound OC1=CC=C(F)N=C1 HTRLNWYWOKWCLV-UHFFFAOYSA-N 0.000 description 1
- 229940124321 AIDS medicine Drugs 0.000 description 1
- KSTJIVVZPWIUGL-UHFFFAOYSA-N CC(C=C(COC(C=C1)=CC=C1[N+]([O-])=O)C=C1C)=C1OC1=NC(NC(C=C2)=CC=C2C#N)=NC=C1 Chemical compound CC(C=C(COC(C=C1)=CC=C1[N+]([O-])=O)C=C1C)=C1OC1=NC(NC(C=C2)=CC=C2C#N)=NC=C1 KSTJIVVZPWIUGL-UHFFFAOYSA-N 0.000 description 1
- ZUGDWCSOJGREHW-UHFFFAOYSA-N CC(C=C(COC1=CC=CC=C1)C=C1C)=C1OC1=NC(NC(C=C2)=CC=C2C#N)=NC=C1 Chemical compound CC(C=C(COC1=CC=CC=C1)C=C1C)=C1OC1=NC(NC(C=C2)=CC=C2C#N)=NC=C1 ZUGDWCSOJGREHW-UHFFFAOYSA-N 0.000 description 1
- HTMBLRVWKFUPJA-UHFFFAOYSA-N CC(C=C(COC1=CC=CN=C1)C=C1C)=C1OC1=NC(NC(C=C2)=CC=C2C#N)=NC=C1 Chemical compound CC(C=C(COC1=CC=CN=C1)C=C1C)=C1OC1=NC(NC(C=C2)=CC=C2C#N)=NC=C1 HTMBLRVWKFUPJA-UHFFFAOYSA-N 0.000 description 1
- JBPNUEZNGXPEPC-UHFFFAOYSA-N CC1=CC(CBr)=CC(C)=C1OC1=NC(NC(C=C2)=CC=C2C#N)=NC=C1 Chemical compound CC1=CC(CBr)=CC(C)=C1OC1=NC(NC(C=C2)=CC=C2C#N)=NC=C1 JBPNUEZNGXPEPC-UHFFFAOYSA-N 0.000 description 1
- UUULLNSEPKDRMC-UHFFFAOYSA-N CC1=CC(COC(C=C2)=CC=C2C#N)=CC(C)=C1OC1=NC(NC(C=C2)=CC=C2C#N)=NC=C1 Chemical compound CC1=CC(COC(C=C2)=CC=C2C#N)=CC(C)=C1OC1=NC(NC(C=C2)=CC=C2C#N)=NC=C1 UUULLNSEPKDRMC-UHFFFAOYSA-N 0.000 description 1
- SQHVNPGCQSLAOV-UHFFFAOYSA-N CC1=CC(COC(C=C2)=CC=C2N)=CC(C)=C1OC1=NC(NC(C=C2)=CC=C2C#N)=NC=C1 Chemical compound CC1=CC(COC(C=C2)=CC=C2N)=CC(C)=C1OC1=NC(NC(C=C2)=CC=C2C#N)=NC=C1 SQHVNPGCQSLAOV-UHFFFAOYSA-N 0.000 description 1
- WYBBCLMQTDDOAJ-UHFFFAOYSA-N CC1=CC(COC(C=C2)=CC=C2OC)=CC(C)=C1OC1=NC(NC(C=C2)=CC=C2C#N)=NC=C1 Chemical compound CC1=CC(COC(C=C2)=CC=C2OC)=CC(C)=C1OC1=NC(NC(C=C2)=CC=C2C#N)=NC=C1 WYBBCLMQTDDOAJ-UHFFFAOYSA-N 0.000 description 1
- ICRCGZNIBUFQRX-UHFFFAOYSA-N CC1=CC(COC(C=CC=C2)=C2C#N)=CC(C)=C1OC1=NC(NC(C=C2)=CC=C2C#N)=NC=C1 Chemical compound CC1=CC(COC(C=CC=C2)=C2C#N)=CC(C)=C1OC1=NC(NC(C=C2)=CC=C2C#N)=NC=C1 ICRCGZNIBUFQRX-UHFFFAOYSA-N 0.000 description 1
- JCCYAKBPCUKEGB-UHFFFAOYSA-N CC1=CC(COC(C=CC=C2)=C2OC)=CC(C)=C1OC1=NC(NC(C=C2)=CC=C2C#N)=NC=C1 Chemical compound CC1=CC(COC(C=CC=C2)=C2OC)=CC(C)=C1OC1=NC(NC(C=C2)=CC=C2C#N)=NC=C1 JCCYAKBPCUKEGB-UHFFFAOYSA-N 0.000 description 1
- GUPDFFPVQKSEMZ-UHFFFAOYSA-N CC1=CC(COC2=C(CO)C=CC=C2)=CC(C)=C1OC1=NC(NC(C=C2)=CC=C2C#N)=NC=C1 Chemical compound CC1=CC(COC2=C(CO)C=CC=C2)=CC(C)=C1OC1=NC(NC(C=C2)=CC=C2C#N)=NC=C1 GUPDFFPVQKSEMZ-UHFFFAOYSA-N 0.000 description 1
- DOEWCCXRHPRYSN-UHFFFAOYSA-N CC1=CC(COC2=CC(C#N)=CN=C2)=CC(C)=C1OC1=NC(NC(C=C2)=CC=C2C#N)=NC=C1 Chemical compound CC1=CC(COC2=CC(C#N)=CN=C2)=CC(C)=C1OC1=NC(NC(C=C2)=CC=C2C#N)=NC=C1 DOEWCCXRHPRYSN-UHFFFAOYSA-N 0.000 description 1
- PEZVBBWPVWXGKP-UHFFFAOYSA-N CC1=CC(COC2=CC(CO)=CC=C2)=CC(C)=C1OC1=NC(NC(C=C2)=CC=C2C#N)=NC=C1 Chemical compound CC1=CC(COC2=CC(CO)=CC=C2)=CC(C)=C1OC1=NC(NC(C=C2)=CC=C2C#N)=NC=C1 PEZVBBWPVWXGKP-UHFFFAOYSA-N 0.000 description 1
- BUJLLGXSDPHZTB-UHFFFAOYSA-N CC1=CC(COC2=CC(OC)=CC=C2)=CC(C)=C1OC1=NC(NC(C=C2)=CC=C2C#N)=NC=C1 Chemical compound CC1=CC(COC2=CC(OC)=CC=C2)=CC(C)=C1OC1=NC(NC(C=C2)=CC=C2C#N)=NC=C1 BUJLLGXSDPHZTB-UHFFFAOYSA-N 0.000 description 1
- NCHFQYQWDQPURP-UHFFFAOYSA-N CC1=CC(COC2=CC=C(CO)C=C2)=CC(C)=C1OC1=NC(NC(C=C2)=CC=C2C#N)=NC=C1 Chemical compound CC1=CC(COC2=CC=C(CO)C=C2)=CC(C)=C1OC1=NC(NC(C=C2)=CC=C2C#N)=NC=C1 NCHFQYQWDQPURP-UHFFFAOYSA-N 0.000 description 1
- DYAZOQYBCXSBQS-UHFFFAOYSA-N CC1=CC(COC2=CC=CC(C#N)=C2)=CC(C)=C1OC1=NC(NC(C=C2)=CC=C2C#N)=NC=C1 Chemical compound CC1=CC(COC2=CC=CC(C#N)=C2)=CC(C)=C1OC1=NC(NC(C=C2)=CC=C2C#N)=NC=C1 DYAZOQYBCXSBQS-UHFFFAOYSA-N 0.000 description 1
- UVUBGXATTDLBFR-UHFFFAOYSA-N CC1=CC(COC2=CC=CN=C2C#N)=CC(C)=C1OC1=NC(NC(C=C2)=CC=C2C#N)=NC=C1 Chemical compound CC1=CC(COC2=CC=CN=C2C#N)=CC(C)=C1OC1=NC(NC(C=C2)=CC=C2C#N)=NC=C1 UVUBGXATTDLBFR-UHFFFAOYSA-N 0.000 description 1
- 241000282414 Homo sapiens Species 0.000 description 1
- 101900297506 Human immunodeficiency virus type 1 group M subtype B Reverse transcriptase/ribonuclease H Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 102000019259 Succinate Dehydrogenase Human genes 0.000 description 1
- 108010012901 Succinate Dehydrogenase Proteins 0.000 description 1
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical group C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 1
- 235000005811 Viola adunca Nutrition 0.000 description 1
- 240000009038 Viola odorata Species 0.000 description 1
- 235000013487 Viola odorata Nutrition 0.000 description 1
- 235000002254 Viola papilionacea Nutrition 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 238000011225 antiretroviral therapy Methods 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 231100000263 cytotoxicity test Toxicity 0.000 description 1
- 239000012154 double-distilled water Substances 0.000 description 1
- 229960001867 guaiacol Drugs 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 229960001627 lamivudine Drugs 0.000 description 1
- JTEGQNOMFQHVDC-NKWVEPMBSA-N lamivudine Chemical compound O=C1N=C(N)C=CN1[C@H]1O[C@@H](CO)SC1 JTEGQNOMFQHVDC-NKWVEPMBSA-N 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000000155 melt Substances 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 229940042402 non-nucleoside reverse transcriptase inhibitor Drugs 0.000 description 1
- 239000002726 nonnucleoside reverse transcriptase inhibitor Substances 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 150000003833 nucleoside derivatives Chemical class 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- CQRYARSYNCAZFO-UHFFFAOYSA-N salicyl alcohol Chemical compound OCC1=CC=CC=C1O CQRYARSYNCAZFO-UHFFFAOYSA-N 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- YRQMBQUMJFVZLF-UHFFFAOYSA-N tert-butyl n-(4-hydroxyphenyl)carbamate Chemical compound CC(C)(C)OC(=O)NC1=CC=C(O)C=C1 YRQMBQUMJFVZLF-UHFFFAOYSA-N 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 238000002723 toxicity assay Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Chemistry (AREA)
- Tropical Medicine & Parasitology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- AIDS & HIV (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明公开了一种如通式I所示的含醚键的二芳基嘧啶类化合物的及其制备方法,以及含有一个或多个含此类化合物的组合物在制备治疗和预防人免疫缺陷病毒(HIV)药物中的应用。
Description
技术领域
本发明属于医药技术领域,具体涉及一种含醚键的二芳基嘧啶类化合物,本发明还涉及这类衍生物的制备方法及其在制备治疗人免疫缺陷病毒(HIV)药物方面的应用。
背景技术
艾滋病,即获得性免疫缺陷综合征(Acquired Immunodeficiency Syndrome,AIDS)。目前艾滋病的临床治疗常采用高效抗逆转录病毒疗法(Highly ActiveAntiroviral Therapy,HAART)。作为HAART的重要组成部分,非核苷类逆转录酶抑制剂(Non-nucleoside Reverse Transcriptase Inhibitors,NNRTIs)因其优异的抗病毒效力、高特异性和低细胞毒性,成为了抗艾滋病药物的研究热点。但是临床治疗中出现的多种耐药株、毒副作用等问题限制了其应用,研发高效低毒抗耐药性的NNRTIs仍是目前抗艾滋病药物研究领域的重大科研任务。
二芳基嘧啶类(DAPYs,Diarylpyrimidines)抑制剂是一类结构具有良好的柔性的NNRTIs,能高效抑制野生型和突变型HIV-1毒株。上市药物利匹韦林(RPV)和依曲韦林(ETR)是DAPY类抑制剂的重要代表,其与HIV-1逆转录酶的晶体复合物结构表明,左翼氰基乙烯基或氰基位于疏水通道,与周围氨基酸产生广泛疏水作用对活性的保持具有重要作用,然而临床治疗中耐药株的出现、药代动力学性质不佳以及高细胞毒性问题限制了其使用。该疏水通道附近的引物夹区域(β12和β13片层)负责将引物的3'-OH定位在聚合酶催化位点,对RT催化活性发挥着重要作用,该区域包含NNIBP中氨基酸残基:F227、W229、L234,且W229高度保守。靶向于高度保守的氨基酸残基,对发现新型高效抗耐药性的化合物具有重要意义。因此,针对引物夹区域,运用基于结构的药物设计理念,对DAPY类化合物的左翼结构引入醚键,通过不同取代的芳杂环替换,以期新引入的基团能与该区域高度保守的氨基酸产生新的作用力,设计了一系列二芳基嘧啶类衍生物。
发明内容
本发明的目的是提供一种含醚键的二芳基嘧啶类化合物及其制备方法,本发明还提供了该类化合物在抗HIV-1活性筛选结果及其在制备抗病毒药物中的应用。
本发明的技术方案如下:
1.含醚键的二芳基嘧啶类化合物
本发明提供了含醚键的二芳基嘧啶类化合物或其药学上可接受的盐,具有通式I所示结构:
上述通式中:
R1,R2各自独立的为:H、卤素、氰基、C1-C6烷基、C1-C6烷氧基、C2-C6烯基、三氟甲基、氨基、羟基或氰基乙烯基;
R3为取代或未取代的苯环、取代或未取代的萘环、取代或未取代的六元杂环、取代或未取代的五元杂环、取代或未取代的六元并五元杂环、取代或未取代的六元并六元杂环、取代或未取代的五元并五元杂环、取代或未取代的苯并五元杂环、取代或未取代的苯并六元杂环,所述的取代基选自甲基、乙基、甲氧基、硝基、氰基、氨基、BOC-氨基、羧基、三氟甲基、卤族、羟基或羟甲基。
根据本发明优选的,
R3为取代或未取代的苯环、取代或未取代的吡啶环。所述的取代基选自甲氧基、硝基、氰基、氨基、BOC-氨基、F、Cl、Br或羟甲基。
根据本发明进一步优选的,通式I所示的含醚键的二芳基嘧啶类化合物是如下化合物之一:
本发明中所述的“药学上可接受的盐”是指在可靠的医药评价范围内,化合物的盐类适于与人或较低等动物的组织相接触而无不适当的毒性、刺激及过敏反应等,具有相当合理的收益/风险比例,通常是水或油可溶的或可分散的,并可有效地用于其预期的用途。包括药学上可接受的酸加成盐和药学上可接受的碱加成盐,在这里是可做预期的用途并与式I化合物的化学性质相容的。适宜的盐的列表参见S.M.Birge等,J.Pharm.Sci.,1977,66,1-19页。
2.含醚键的二芳基嘧啶类化合物的制备方法
I系列化合物的合成路步骤如下:以2-甲硫基-4-嘧啶酮为起始原料,与4-氨基苯腈发生熔融反应,得到中间体2;三氯氧磷作为溶剂和反应试剂,与2生成中间体3;3与不同取代的4-羟基苯甲醛发生取代反应得到中间体4;4与硼氢化钠发生还原反应得到中间体5;5经三溴化磷溴化得到关键中间体6;在碱性条件下,6与不同取代的酚类化合物发生亲核取代反应得到目标化合物I;
合成路线如下:
试剂和条件:(i)4-氨基苯腈,180℃;(ii)三氯氧磷,105℃;(iii)碳酸钾,N,N-二甲基甲酰胺,100℃;(iv)硼氢化钠,甲醇,0℃~r.t.;(v)三溴化磷,二氯甲烷,0℃~r.t.;(vi)取代的酚类化合物,氢氧化钾,碘化钾,乙腈,80℃;
其中,R1、R2、R3如通式I中所述。
所述的取代的酚类化合物为:取代或未取代的苯酚、取代或未取代的羟基吡啶,取代基选自甲氧基、硝基、氰基、氨基、BOC-氨基、F、Cl、Br或羟甲基。
本发明所述的室温为20-30℃。
3.含醚键的二芳基嘧啶类化合物的抗HIV-1野生株及突变株的活性及应用
对按照上述方法合成的二芳基嘧啶类衍生物进行了细胞水平的抗野生型HIV-1(IIII),单突变株L100I、K103N、Y181C、Y188L、E138K以及双突变株F227L/V106A、RES056(K103N/Y181C)的活性筛选,以齐多夫定(AZT)、奈韦拉平(NVP)、依法韦伦(EFV)、依曲韦林(ETR)为阳性对照。结果如表1和表2所示。结果表明所有化合物对野生型HIV-1表现出单个纳摩尔到几百个的纳摩尔的活性,其中化合物I-2(EC50=7.6nM)活性最为突出,优于阳性药物AZT(EC50=0.127μM)和NVP(EC50=0.023μM),值得注意的是,I-2(CC50>279.33μM,SI>36610.9)表现出低细胞毒性和高选择性。对于所测HIV-1突变株,大部分化合物对K103N和E138K表现出几十到几百个纳摩尔的抑制活性。因此该类二芳基嘧啶类化合物具有进一步研发的价值,可作为抗HIV-1的先导化合物加以利用。
本发明的含醚键的二芳基嘧啶类化合物可作为非核苷类HIV-1抑制剂应用。具体地说,作为HIV-1抑制剂用于制备抗艾滋病药物。
一种抗HIV-1药物组合物,包括本发明的含有反式双键的二芳基嘧啶类化合物和一种或多种药学上可接受载体或赋形剂。
本发明提供了结构全新的含醚键的二芳基嘧啶类化合物及其制备方法,本发明还提供了化合物抗HIV-1活性筛选结果及其在抗病毒领域中的首次应用。经过试验证明,本发明含醚键的二芳基嘧啶类化合物可作为HIV-1抑制剂应用。具体地说,作为HIV-1抑制剂用于制备抗艾滋病药物。
具体实施方式
通过下述实例有助于理解本发明,但是不能限制本发明的内容。
实施例中所涉及的合成路线如下:
实施例1:4-((4-(4-甲酰基-2,6-二甲基苯氧基)嘧啶-2-基)氨基)苄腈(中间体4)的制备。
称取起始原料2-(甲硫基)嘧啶-4(3H)-酮(4.97g,35.00mmol)和4-氨基苯甲腈(4.96g,42.00mmol),将两者置于250mL圆底烧瓶中混合均匀。在氮气(N2)保护的条件下,缓慢升温到180℃,熔融反应8h。待反应冷却至80℃,向反应瓶中加入50ml乙腈,进行超声处理。超声所得浑浊液过滤,滤饼用乙腈洗涤至TLC检测无原料残留。干燥滤饼并收集,得淡黄色固体粗品,即中间体2。收率:62%;ESI-MS:m/z 213.3[M+H]+,C11H8N4O(212.12).
称取中间体2(3.00g,14.14mmol)溶于20mL三氯氧磷中,105℃加热回流反应2h。TLC检测反应完全后,将反应液缓慢滴加至300mL冰水混合物中,有黄色沉淀生成。搅拌0.5h后过滤,干燥滤饼即得中间体3。收率:65%。1H NMR(400MHz,DMSO-d6)δ10.58(s,1H,NH),8.55(d,J=5.2Hz,1H,C6-pyrimidine-H),7.87(dd,4H,Ph-H),7.13(d,J=5.2Hz,1H,C6-pyrimidine-H);ESI-MS:m/z 231.2[M+H]+,C11H7ClN4(230.04).
称取中间体3(3.00g,13.04mmol),3,5-二甲基-4-羟基苯甲醛(2.35g,15.65mmol),无水碳酸钾(3.60g,26.08mmol)溶于5mL DMF溶剂中,加热至100℃反应10h。经TLC检测反应完全后,待反应液冷却至室温,加入30mL饱和氯化钠溶液,有棕色固体产生。过滤干燥得中间体4。收率:61%。
波谱数据:1H NMR(400MHz,DMSO-d6)δ10.13(s,1H,-CHO),10.03(s,1H,NH),8.50(d,J=5.6Hz,1H,C6-pyrimidine-H),7.80(s,2H,Ph-H),7.56(d,J=8.6Hz,2H,Ph-H),7.44(d,J=8.7Hz,2H,Ph-H),6.71(d,J=5.6Hz,1H,C5-pyrimidine-H),2.17(s,6H,2×CH3).ESI-MS:m/z345.4[M+H]+,C20H16N4O2(344.13).
实施例2:4-((4-(4-(羟甲基)-2,6-二甲基苯氧基)嘧啶-2-基)氨基)苯甲腈(中间体5)的制备。
称取4(1.00g,2.91mmol)溶于50mL的甲醇溶液中,然后在冰浴条件下,将硼氢化钠(0.10g,2.91mmol)分批次缓慢加入反应液中,反应0.5h。将反应移至室温继续反应4h。TLC检测反应完全后,减压蒸干溶剂,然后向残留底物中加入20mL饱和食盐水溶液,乙酸乙酯萃取(3×20mL),收集有机相,无水硫酸钠干燥、过滤和浓缩。快速柱层析分离得到中间体5,白色固体。收率:45.3%。
波谱数据:1H NMR(400MHz,DMSO-d6)δ10.11(s,1H,NH),8.44(d,J=5.6Hz,1H,C6-pyrimidine-H),7.59(d,J=8.7Hz,2H,Ph-H),7.50(d,J=8.8Hz,2H,Ph-H),7.15(s,2H,Ph-H),6.60(d,J=5.6Hz,1H,C5-pyrimidine-H),5.25(t,J=5.6Hz,1H,OH),4.52(d,J=5.6Hz,2H,CH2),2.07(s,6H,2×CH3).ESI-MS:m/z 347.3[M+H]+,C20H18N4O2(346.14).
实施例3:4-((4-(4-(溴甲基)-2,6-二甲基苯氧基)嘧啶-2-基)氨基)苯甲腈(中间体6)的制备。
称取中间体5(1.00g,2.88mmol)溶于10mL的二氯甲烷溶液中,然后在冰浴条件下,将三溴化磷(0.33mL,3.46mmol)溶于二氯甲烷并逐滴加入反应液内,反应2h。移至室温继续反应2h。TLC检测反应完全后,减压蒸干溶剂,然后向残留底物中加入20mL饱和食盐水溶液,乙酸乙酯萃取(3×20mL),收集有机相,无水硫酸钠干燥、过滤和浓缩。快速柱层析分离得到中间体6,白色固体。收率:51%。
波谱数据:1H NMR(400MHz,DMSO-d6)δ10.14(s,1H,NH),8.47(d,J=5.6Hz,1H,C6-pyrimidine-H),7.56(d,J=8.6Hz,2H,Ph-H),7.52(d,J=8.2Hz,2H,Ph-H),7.32(s,2H,Ph-H),6.66(d,J=5.6Hz,1H,C5-pyrimidine-H),4.79(d,J=18.3Hz,2H,CH2),2.07(s,6H,2×CH3).ESI-MS:m/z 409.4[M+H]+,C20H17BrN4O(408.06).
实施例4:4-((4-(2,6-二甲基-4-(苯氧基甲基)苯氧基)嘧啶-2-基)氨基)苄腈(I-1)的制备。
称取中间体6(0.25mmol)、苯酚(0.30mmol)、KOH(0.30mmol)以及碘化钾(0.30mmol),混于10mL乙腈中,80℃加热回流反应4h。待TLC检测反应完全后,减压蒸干溶剂,加入20ml饱和食盐水,并用乙酸乙酯萃取(3×20mL)。收集有机相,经无水硫酸钠干燥、过滤和浓缩。快速柱层析分离得到I-1(二氯甲烷/甲醇体系)。
白色固体,收率:50%,熔点:179-182℃。
波谱数据:1H NMR(400MHz,DMSO-d6)δ10.17(s,1H,NH),8.46(d,J=5.6Hz,1H,C6-pyrimidine-H),7.57(d,J=8.5Hz,2H,Ph-H),7.49(d,J=8.6Hz,2H,Ph-H),7.33(d,J=9.8Hz,4H,Ph-H),7.09(d,J=8.0Hz,2H,Ph-H),6.97(t,J=7.3Hz,1H,Ph-H),6.65(d,J=5.6Hz,1H,C5-pyrimidine-H),5.08(s,2H,CH2),2.09(s,6H,2×CH3).13C NMR(100MHz,DMSO-d6)δ168.97,160.76,159.68,158.95,149.60,145.07,134.90,133.11,130.90,130.01,129.05,121.24,119.90,118.57,115.13,102.90,99.33,69.39,16.55.ESI-MS:m/z423.17[M+H]+.C26H22N4O2(422.17).
实施例5:4-((4-(4-((4-氰基苯氧基)甲基)-2,6-二甲基苯氧基)嘧啶-2-基)氨基)苄腈(I-2)的制备。
操作同上,不同的是使用4-羟基苯甲腈,白色固体,收率:62%,熔点:202-205℃。
波谱数据:1H NMR(400MHz,DMSO-d6)δ10.09(s,1H,NH),8.40(d,J=5.6Hz,1H,C6-pyrimidine-H),7.76-7.71(m,2H,Ph-H),7.50(d,J=8.6Hz,2H,Ph-H),7.41(d,J=8.6Hz,2H,Ph-H),7.27(s,2H,Ph-H),7.19(d,J=8.7Hz,2H,Ph-H),6.58(d,J=5.6Hz,1H,C5-pyrimidine-H),5.13(s,2H,CH2),2.02(s,6H,2×CH3).13C NMR(100MHz,DMSO-d6)δ168.93,162.37,160.80,159.67,149.85,145.07,134.71,133.94,133.09,131.07,129.29,119.91,119.55,118.58,116.27,103.57,102.89,99.33,70.05,16.54.ESI-MS:m/z 448.38[M+H]+.C27H21N5O2(447.17).
实施例6:3-((4-((2-((4-氰基苯基)氨基)嘧啶-4-基)氧基)-3,5-二甲基苄基)氧基)苄腈(I-3)的制备。
操作同上,不同的是使用3-氰基苯酚,白色固体,收率:54%,熔点:199-202℃。
波谱数据:1H NMR(400MHz,DMSO-d6)δ10.17(s,1H,NH),8.46(d,J=5.6Hz,1H,C6-pyrimidine-H),7.57(d,J=8.5Hz,2H,Ph-H),7.49(d,J=8.6Hz,2H,Ph-H),7.33(d,J=9.8Hz,4H,Ph-H),7.09(d,J=8.0Hz,2H,Ph-H),6.97(t,J=7.3Hz,1H,Ph-H),6.65(d,J=5.6Hz,1H,C5-pyrimidine-H),5.08(s,2H,CH2),2.09(s,6H,2×CH3).13C NMR(100MHz,DMSO-d6)δ168.94,160.79,159.67,159.08,149.82,145.07,134.10,133.09,131.36,131.04,129.31,125.26,121.00,119.92,119.10,118.59,118.03,112.83,102.90,99.33,70.11,16.54.ESI-MS:m/z 448.38[M+H]+.C27H21N5O2(447.17).
实施例7:2-((4-((2-((4-氰基苯基)氨基)嘧啶-4-基)氧基)-3,5-二甲基苄基)氧基)苄腈(I-4)的制备。
操作同上,不同的是使用2-氰基苯酚,白色固体,收率:61%,熔点:198-201℃。
波谱数据:1H NMR(400MHz,DMSO-d6)δ10.15(s,1H,NH),8.47(d,J=5.6Hz,1H,C6-pyrimidine-H),7.77(dd,J=7.7,1.7Hz,1H,Ph-H),7.70(td,J=8.0,7.5,1.7Hz,1H,Ph-H),7.61(d,J=8.5Hz,2H,Ph-H),7.48(d,J=8.6Hz,2H,Ph-H),7.43(d,J=8.6Hz,1H,Ph-H),7.35(s,2H,Ph-H),7.14(t,J=7.6Hz,1H,Ph-H),6.65(d,J=5.6Hz,1H,C5-pyrimidine-H),5.30(s,2H,CH2),2.11(s,6H,2×CH3).13C NMR(100MHz,DMSO-d6)δ168.93,160.72,160.47,159.71,149.73,145.01,135.52,134.30,133.91,133.17,131.07,128.77,121.84,119.86,118.57,116.88,114.01,103.03,101.35,99.42,70.34.ESI-MS:m/z 448.30[M+H]+.C27H21N5O2(447.17).
实施例8:4-((4-(4-((4-甲氧基苯氧基)甲基)-2,6-二甲基苯氧基)嘧啶-2-基)氨基)苄腈(I-5)的制备。
操作同上,不同的是使用4-甲氧基苯酚,白色固体,收率:63%,熔点:188-191℃。
波谱数据:1H NMR(400MHz,DMSO-d6)δ10.16(s,1H,NH),8.46(d,J=5.6Hz,1H,C6-pyrimidine-H),7.58(d,J=8.5Hz,2H,Ph-H),7.51(d,J=8.6Hz,2H,Ph-H),7.30(s,2H,Ph-H),7.06–7.00(m,2H,Ph-H),6.92–6.85(m,2H,Ph-H),6.65(d,J=5.6Hz,1H,C5-pyrimidine-H),5.02(s,2H,CH2),3.71(s,3H,CH3),2.09(s,6H,2×CH3).13C NMR(100MHz,DMSO-d6)δ168.98,160.76,159.68,153.97,153.01,149.52,145.08,135.15,133.12,130.85,128.95,119.91,118.60,116.03,115.10,102.90,99.33,70.00,55.82,16.55.ESI-MS:m/z 453.20[M+H]+.C27H24N4O3(452.18).
实施例9:4-((4-(4-((3-甲氧基苯氧基)甲基)-2,6-二甲基苯氧基)嘧啶-2-基)氨基)苄腈(I-6)的制备。
操作同上,不同的是使用3-甲氧基苯酚,白色固体,收率:63%,熔点:149-152℃。
波谱数据:1H NMR(400MHz,DMSO-d6)δ10.17(s,1H,NH),8.47(d,J=5.6Hz,1H,C6-pyrimidine-H),7.59(d,J=8.5Hz,2H,Ph-H),7.50(d,J=8.6Hz,2H,Ph-H),7.32(s,2H,Ph-H),7.22(t,J=8.2Hz,1H,Ph-H),6.71–6.62(m,3H,Ph-H),6.56(dd,J=8.2,2.3Hz,1H,C5-pyrimidine-H),5.08(s,2H,CH2),3.76(s,3H,CH3),2.10(s,6H,2×CH3).13C NMR(100MHz,DMSO-d6)δ168.97,161.04,160.75,160.23,159.69,149.59,145.07,134.85,133.12,130.89,130.45,129.02,119.90,118.60,107.34,107.06,102.92,101.37,99.33,69.56,55.55,16.55.ESI-MS:m/z453.25[M+H]+.C27H24N4O3(452.18).
实施例10:4-((4-(4-((2-甲氧基苯氧基)甲基)-2,6-二甲基苯氧基)嘧啶-2-基)氨基)苄腈(I-7)的制备。
操作同上,不同的是使用2-甲氧基苯酚,白色固体,收率:58%,熔点:208-211℃。
波谱数据:1H NMR(400MHz,DMSO-d6)δ10.15(s,1H,NH),8.47(d,J=5.7Hz,1H,C6-pyrimidine-H),7.63(d,J=8.3Hz,2H,Ph-H),7.52(d,J=8.5Hz,2H,Ph-H),7.31(s,2H,Ph-H),7.12(d,J=7.4Hz,1H,Ph-H),7.01(d,J=7.5Hz,1H,Ph-H),6.92(p,J=7.4Hz,2H,Ph-H),6.65(d,J=5.7Hz,1H,C5-pyrimidine-H),5.06(s,2H,CH2),3.78(s,3H,CH3),2.10(s,6H,2×CH3).13C NMR(100MHz,DMSO-d6)δ168.99,160.65,159.72,149.72,149.50,148.45,145.05,135.02,133.19,130.81,129.05,121.71,121.08,119.89,118.66,114.20,112.62,102.99,99.47,70.27,55.95,16.58.ESI-MS:m/z 453.32[M+H]+.C27H24N4O3(452.18).
实施例11:4-((4-(4-((4-(羟甲基)苯氧基)甲基)-2,6-二甲基苯氧基)嘧啶-2-基)氨基)苄腈(I-8)的制备。
操作同上,不同的是使用对羟基苯甲醇,白色固体,收率:50%,熔点:209-212℃。
波谱数据:1H NMR(400MHz,DMSO-d6)δ10.16(s,1H,NH),8.46(d,J=5.6Hz,1H,C6-pyrimidine-H),7.57(d,J=8.6Hz,2H,Ph-H),7.51(d,J=8.6Hz,2H,Ph-H),7.32(s,2H,Ph-H),7.26(d,J=8.1Hz,2H,Ph-H),7.04(d,J=8.2Hz,2H,Ph-H),6.65(d,J=5.6Hz,1H,C5-pyrimidine-H),5.07(s,3H,CH2,OH),4.43(d,J=5.7Hz,2H,CH2,),2.09(s,6H,2×CH3).13CNMR(100MHz,DMSO-d6)δ168.98,160.77,159.68,157.87,149.58,145.08,135.31,134.97,133.11,130.88,129.05,128.42,119.91,118.59,114.73,102.90,99.33,69.53,63.02,16.55.ESI-MS:m/z 451.54[M-H]-.C27H24N4O3(452.18).
实施例12:4-((4-(4-((3-(羟甲基)苯氧基)甲基)-2,6-二甲基苯氧基)嘧啶-2-基)氨基)苄腈(I-9)的制备。
操作同上,不同的是使用3-羟基苯甲醇,白色固体,收率:50%,熔点:147-150℃。
波谱数据:1H NMR(400MHz,DMSO-d6)δ10.17(s,1H,NH),8.47(d,J=5.7Hz,1H,C6-pyrimidine-H),7.59(d,J=8.7Hz,2H,Ph-H),7.51(d,J=8.4Hz,2H,Ph-H),7.32(s,2H,Ph-H),7.27(t,J=7.9Hz,1H,Ph-H),7.05(s,1H,Ph-H),6.94(d,J=7.8Hz,2H,Ph-H),6.65(d,J=5.6Hz,1H,C5-pyrimidine-H),5.19(t,J=5.8Hz,1H,OH),5.08(s,2H,CH2),4.51(d,J=5.5Hz,2H,CH2),2.09(s,6H,2×CH3).13C NMR(100MHz,DMSO-d6)δ168.98,160.76,159.68,158.94,149.57,145.08,144.86,134.96,133.13,130.88,129.63,129.05,119.91,119.29,118.60,113.29,113.08,102.91,99.35,69.42,63.24,16.56.ESI-MS:m/z 453.48[M+H]+.C27H24N4O3(452.18).
实施例13:4-((4-(4-((2-(羟甲基)苯氧基)甲基)-2,6-二甲基苯氧基)嘧啶-2-基)氨基)苄腈(I-10)的制备。
操作同上,不同的是使用水杨醇,白色固体,收率:45%,熔点:179-182℃。
波谱数据:1H NMR(400MHz,DMSO-d6)δ10.21–10.16(m,1H,NH),8.46(d,J=5.6Hz,1H,C6-pyrimidine-H),7.62(d,J=8.5Hz,2H,Ph-H),7.49(d,J=8.6Hz,2H,Ph-H),7.43(dd,J=7.5,1.7Hz,1H,Ph-H),7.31(s,2H,Ph-H),7.22(td,J=7.8,1.8Hz,1H,Ph-H),7.08(d,J=8.2Hz,1H,Ph-H),6.97(t,J=7.4Hz,1H,Ph-H),6.64(d,J=5.6Hz,1H,C5-pyrimidine-H),5.34(s,1H,OH),5.14(s,2H,CH2),4.60(s,2H,CH2),2.10(s,6H,2×CH3).13CNMR(100MHz,DMSO-d6)δ169.04,160.47,159.54,155.60,149.33,144.99,135.31,133.14,131.24,130.82,128.25,128.01,127.63,120.92,119.84,118.68,112.08,103.03,99.43,69.30,58.43,16.64.ESI-MS:m/z 453.38[M+H]+.C27H24N4O3(452.18).
实施例14:4-((4-(2,6-二甲基-4-((吡啶-3-基氧基)甲基)苯氧基)嘧啶-2-基)氨基)苄腈(I-11)的制备。
操作同上,不同的是使用3-羟基吡啶,白色固体,收率:47%,熔点:237-240℃。
波谱数据:1H NMR(400MHz,DMSO-d6)δ10.16(s,1H,NH),8.46(d,J=5.6Hz,1H,C6-pyrimidine-H),7.66(t,J=2.3Hz,1H,pyridine-H),7.62(d,J=5.5Hz,1H,Ph-H),7.54(d,J=8.5Hz,2H,Ph-H),7.39(s,2H,Ph-H),7.38(d,J=8.7Hz,2H,Ph-H),7.32(dd,J=9.0,5.4Hz,1H,pyridine-H),6.96(dd,J=8.9,2.7Hz,1H,pyridine-H),6.65(d,J=5.6Hz,1H,C5-pyrimidine-H),5.38(s,2H,CH2),2.08(s,6H,2×CH3).13C NMR(100MHz,DMSO-d6)δ168.79,160.82,159.65,150.23,144.99,134.09,133.33,133.26,133.04,131.54,129.48,127.51,119.80,118.48,102.93,99.39,62.23,16.58.ESI-MS:m/z 424.10[M+H]+.C25H21N5O2(423.17).
实施例15:3-((4-((2-((4-氰基苯基)氨基)嘧啶-4-基)氧基)-3,5-二甲基苄基)氧基)吡啶甲腈(I-12)的制备。
操作同上,不同的是使用2-氰基-3-羟基吡啶,白色固体,收率:41%,熔点:245-248℃。
波谱数据:1H NMR(400MHz,DMSO-d6)δ10.14(s,1H,NH),8.47(d,J=5.6Hz,1H,C6-pyrimidine-H),8.36(d,J=4.5Hz,1H,pyridine-H),7.97(d,J=8.7Hz,1H,pyridine-H),7.76(dd,J=8.8,4.5Hz,1H,pyridine-H),7.61(d,J=8.5Hz,2H,Ph-H),7.50(d,J=8.5Hz,2H,Ph-H),7.36(s,2H,Ph-H),6.65(d,J=5.6Hz,1H,C5-pyrimidine-H),5.36(s,2H,CH2),2.11(s,6H,2×CH3).13C NMR(100MHz,DMSO-d6)δ168.91,160.75,159.70,158.34,149.91,145.00,143.70,133.33,133.17,131.18,129.48,128.99,122.69,122.61,119.85,118.58,115.95,103.03,99.41,70.77,16.63.ESI-MS:m/z 447.24[M-H]-.C26H20N6O2(448.16).
实施例16:5-((4-((2-((4-氰基苯基)氨基)嘧啶-4-基)氧基)-3,5-二甲基苄基)氧基)烟腈(I-13)的制备。
操作同上,不同的是使用3-氰基-5-羟基吡啶,白色固体,收率:52%,熔点:195-198℃。
波谱数据:1H NMR(400MHz,DMSO-d6)δ10.09(s,1H,NH),8.64(d,J=2.9Hz,1H,pyridine-H),8.58(d,J=1.5Hz,1H,pyridine-H),8.40(d,J=5.6Hz,1H,C6-pyrimidine-H),8.05(t,J=2.3Hz,1H,pyridine-H),7.51(d,J=8.5Hz,2H,Ph-H),7.42(d,J=8.6Hz,2H,Ph-H),7.28(s,2H,Ph-H),6.59(d,J=5.6Hz,1H,C5-pyrimidine-H),5.17(s,2H,CH2),2.03(s,6H,2×CH3).13C NMR(100MHz,DMSO-d6)δ168.91,160.83,159.67,154.64,149.98,145.06,145.01,143.13,133.54,133.10,131.15,129.49,124.45,119.92,118.60,117.21,109.75,102.91,99.34,70.61,16.54.ESI-MS:m/z 447.27[M-H]+.C26H20N6O2(448.16).
实施例17:4-((4-(4-(((6-氟吡啶-3-基)氧基)甲基)-2,6-二甲基苯氧基)嘧啶-2-基)氨基)苄腈(I-14)。
操作同上,不同的是使用2-氟-5-羟基吡啶,白色固体,收率:61%,熔点:185-188℃。
波谱数据:1H NMR(400MHz,DMSO-d6)δ10.16(s,1H,NH),8.47(d,J=5.6Hz,1H,C6-pyrimidine-H),8.04(dd,J=3.1,1.8Hz,1H,pyridine-H),7.74(ddd,J=9.4,6.7,3.1Hz,1H,pyridine-H),7.58(d,J=8.6Hz,2H,Ph-H),7.49(d,J=8.6Hz,2H,Ph-H),7.34(s,2H,Ph-H),7.16(dd,J=8.9,3.4Hz,1H,pyridine-H),6.65(d,J=5.6Hz,1H,C5-pyrimidine-H),5.17(s,2H,CH2),2.10(s,6H,2×CH3).13C NMR(100MHz,DMSO-d6)δ168.93,160.80,159.67,158.86,156.58,153.59,153.55,149.81,145.06,134.15,133.86,133.70,133.11,131.04,129.26,128.98,128.90,119.91,118.59,110.50,110.10,102.89,99.32,70.73,16.54.ESI-MS:m/z 442.61[M+H]+.C25H20FN5O2(441.16).
实施例18:4-((4-(2,6-二甲基-4-((4-硝基苯氧基)甲基)苯氧基)嘧啶-2-基)氨基)苄腈(I-15)的制备。
操作同上,不同的是使用4-硝基苯酚,白色固体,收率:71%,熔点:233-236℃。
波谱数据:1H NMR(400MHz,DMSO-d6)δ10.20(s,1H,NH),8.48(d,J=5.6Hz,1H,C6-pyrimidine-H),8.25(d,J=8.8Hz,2H,Ph-H),7.59(d,J=8.6Hz,2H,Ph-H),7.49(d,J=8.5Hz,2H,Ph-H),7.37(s,2H,Ph-H),7.31(d,J=8.9Hz,2H,Ph-H),6.67(d,J=5.6Hz,1H,C5-pyrimidine-H),5.27(s,2H,CH2),2.11(s,6H,2×CH3).13C NMR(100MHz,DMSO-d6)δ168.91,164.18,160.80,159.66,149.93,145.08,141.45,133.73,133.06,131.11,129.33,126.36,119.92,118.57,115.71,102.86,99.30,70.56,16.53.ESI-MS:m/z 468.19[M+H]+.C26H21N5O4(467.16).
实施例19:(4-((4-((2-((4-氰基苯基)氨基)嘧啶-4-基)氧基)-3,5-二甲基苄基)氧基)苯基)氨基甲酸叔丁酯(I-16)的制备。
操作同上,不同的是使用4-(BOC-氨基)酚,白色固体,收率:73%,熔点:184-187℃。
波谱数据:1H NMR(400MHz,DMSO-d6)δ10.15(s,1H,NH),9.14(s,1H,NH),8.46(d,J=5.7Hz,1H,C6-pyrimidine-H),7.58(d,J=8.7Hz,2H,Ph-H),7.51(d,J=8.7Hz,2H,Ph-H),7.38(d,J=8.5Hz,2H,Ph-H),7.31(s,2H,Ph-H),7.02–6.96(m,2H,Ph-H),6.64(d,J=5.7Hz,1H,C5-pyrimidine-H),5.01(s,2H,CH2),2.09(s,6H,2×CH3),1.47(s,9H,3×CH3).13C NMR(100MHz,DMSO-d6)δ168.97,160.77,159.67,154.19,153.40,149.57,145.07,134.99,133.34,133.12,130.85,129.14,120.11,119.90,118.60,115.14,102.90,99.32,79.13,69.75,28.65,16.54.ESI-MS:m/z 538.16[M+H]+.C31H31N5O4(537.24).
实施例20:4-((4-(4-((4-氨基苯氧基)甲基)-2,6-二甲基苯氧基)嘧啶-2-基)氨基)苄腈(I-17)的制备。
称取化合物I-16(0.2g,0.37mmol)溶于5mL二氯甲烷中,加入2mL三氟乙酸,室温搅拌3h。TLC检测反应完全后,向反应液中加饱和碳酸氢钠溶液,直至pH8~9。二氯甲烷(3×20mL)萃取,有机相经无水硫酸钠干燥、过滤和浓缩,快速柱层析分离得I-17。
白色固体,收率:65%,熔点:241-244℃。
波谱数据:1H NMR(400MHz,DMSO-d6)δ10.17(s,1H,NH),9.35(s,2H,NH2),8.47(d,J=5.7Hz,1H,C6-pyrimidine-H),7.56(d,J=8.7Hz,2H,Ph-H),7.50(d,J=8.6Hz,2H,Ph-H),7.32(s,2H,Ph-H),7.21(d,J=8.5Hz,2H,Ph-H),7.14(d,J=8.5Hz,2H,Ph-H),6.66(d,J=5.7Hz,1H,C5-pyrimidine-H),5.09(s,2H,CH2),2.09(s,6H,2×CH3).13C NMR(100MHz,DMSO-d6)δ168.95,160.83,159.65,157.18,149.71,145.09,134.59,133.11,130.96,129.20,127.78,123.35,119.95,118.57,116.11,102.85,99.31,69.97,16.54.ESI-MS:m/z438.57[M+H]+.C26H23N5O2(437.19).
实施例21:目标化合物的体外抗HIV活性测试
(1)测试原理:MTT即噻唑蓝,其检测原理为活细胞线粒体中的琥珀酸脱氢酶将MTT还原为水不溶性的蓝紫色结晶甲臜(Formazan)并沉积在细胞中,而死细胞没有此功能。甲臜能被二甲基亚砜(DMSO)所溶解,溶液的颜色深浅与细胞所含的甲臜量成正比。用酶标仪测定最终溶液在一定波长处的吸光度,该吸光度值即可间接反映出活细胞数量[73]。
(2)实验材料:
①HIV-1野生株(IIIB)、HIV-2毒株(ROD)、HIV-1突变株(L100I、K103N、Y181C、Y188L、E138K、F227L+V106A和RES056)、MT-4细胞:均由比利时鲁汶大学Rega研究所提供。
②MTT:购自Acros Organics,Geel,Belgium。
③样品处理:测试前,将待测样品溶解于DMSO溶液配成合适浓度,然后用双蒸水作5倍稀释,各5个稀释度。
④阳性对照药:齐多夫定(AZT)、拉米夫定(3TC)、奈韦拉平(NVP)、依法韦仑(EFV)和依曲韦林(ETR)。
(3)实验方法:
在96孔细胞培养板中依次加入50μL含1×104MT-4细胞培养液、20μL HIV感染的MT-4细胞混悬液或者空白培养基(未感染细胞,用于毒性测定)、不同浓度的待测化合物溶液或者阳性对照药物(每个浓度设计3个复孔)。在5%CO2氛围,37℃,相对湿度≥95%条件下,将细胞培养5天。然后向每孔加入20mL MTT溶液(5mg/mL)。培养2小时后加入150μL DMSO溶液,使用酶标仪测定反应溶液吸收度(测定波长540nm,参比波长690nm)。保护50%MT-4细胞不发生病变的化合物浓度,即为目标化合物体外抗HIV的活性(EC50)。化合物使50%未感染HIV的正常细胞死亡的浓度,即为细胞毒性(CC50),并根据两者计算选择性指数(selectivity index,SI=CC50/EC50)。
(4)实验结果:
按照上述方法对合成的代表化合物进行了细胞水平的抗野生型HIV-1(IIIB)和HIV-2(ROD),单突变株L100I、K103N、Y181C、Y188L、E138K以及双突变株F227L/V106A、RES056(K103N/Y181C)的活性筛选,结果如表1和表2所示。
表1.化合物抗HIV-1IIIB、ROD活性以及细胞毒性测试结果
aEC50:保护50%MT-4细胞不发生病变的化合物浓度。bCC50:使50%未感染HIV的正常细胞死亡的化合物浓度。cSI:选择性指数,CC50/EC50。
表2.化合物抗HIV-1突变株活性测试结果
aEC50:保护50%MT-4细胞不发生病变的化合物浓度。
结论;细胞水平活性结果表明,所有化合物对野生型HIV-1均具有抑制活性,其中I-2(EC50=7.6nM)、I-4(EC50=7.8nM)和I-12(EC50=7.8nM)的活性最为突出,优于阳性药物AZT(EC50=0.127μM)和NVP(EC50=0.023μM),且I-2(CC50>279.33μM)的细胞毒性低。对于所测HIV-1突变株,大部分化合物对K103N和E138K表现出几十到几百个纳摩尔的抑制活性,特别是对于K103N突变株,其中化合物I-2(EC50=28nM)、I-12(EC50=35nM)和I-13(EC50=28nM)较突出,优于NVP(EC50=7.495μM)和EFV(EC50=95nM)。对于E138K突变株,I-2(EC50=44nM)和I-12(EC50=46nM)的活性相当,均优于NVP(EC50=149nM)。因此该类二芳基嘧啶类衍生物具有进一步研发的价值,可作为抗HIV-1的先导化合物加以利用。
Claims (6)
2.如权利要求1所述的含醚键的二芳基嘧啶类化合物,其特征在于:
R3为取代或未取代的苯环、取代或未取代的吡啶环;所述的取代基选自甲氧基、硝基、氰基、氨基、BOC-氨基、F、Cl、Br或羟甲基。
4.如权利要求1所述的含醚键的二芳基嘧啶类化合物的制备方法,步骤如下:
以2-甲硫基-4-嘧啶酮为起始原料,与4-氨基苯腈发生熔融反应,得到中间体2;三氯氧磷作为溶剂和反应试剂,与中间体2生成中间体3;3与不同取代的4-羟基苯甲醛发生取代反应得到中间体4;4与硼氢化钠发生还原反应得到中间体5;5经三溴化磷溴化得到关键中间体6;在碱性条件下,6与不同取代的酚类化合物发生亲核取代反应得到目标化合物I;
合成路线如下:
试剂和条件:(i)4-氨基苯腈,180℃;(ii)三氯氧磷,105℃;(iii)碳酸钾,N,N-二甲基甲酰胺,100℃;(iv)硼氢化钠,甲醇,0℃~r.t.;(v)三溴化磷,二氯甲烷,0℃~r.t.;(vi)取代的酚类化合物,氢氧化钾,碘化钾,乙腈,80℃;
其中,R1,R2,R3如通式I中所述;
所述的取代的酚类化合物为:取代或未取代的苯酚、取代或未取代的羟基吡啶,取代基选自甲氧基、硝基、氰基、氨基、BOC-氨基、F、Cl、Br或羟甲基。
5.一种如权利要求1-3任一项所述的含醚键的二芳基嘧啶类化合物在制备治疗和预防人免疫缺陷病毒药物中的应用。
6.一种药物组合物,包含权利要求1-3任一项所述含醚键的二芳基嘧啶类化合物和一种或多种药学上可接受载体或赋形剂。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202211149680.4A CN115490642A (zh) | 2022-09-21 | 2022-09-21 | 一种含醚键的二芳基嘧啶类化合物及其制备方法与应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202211149680.4A CN115490642A (zh) | 2022-09-21 | 2022-09-21 | 一种含醚键的二芳基嘧啶类化合物及其制备方法与应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN115490642A true CN115490642A (zh) | 2022-12-20 |
Family
ID=84470391
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202211149680.4A Pending CN115490642A (zh) | 2022-09-21 | 2022-09-21 | 一种含醚键的二芳基嘧啶类化合物及其制备方法与应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN115490642A (zh) |
Citations (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1541215A (zh) * | 2001-08-13 | 2004-10-27 | ղɭҩҵ����˾ | 抑制hiv的嘧啶衍生物 |
CN102151270A (zh) * | 2003-02-07 | 2011-08-17 | 詹森药业有限公司 | 预防hiv感染的嘧啶衍生物 |
CN103483272A (zh) * | 2013-09-29 | 2014-01-01 | 山东大学 | 间二芳烃-多取代嘧啶类衍生物及其制备方法与应用 |
CN104876860A (zh) * | 2015-05-07 | 2015-09-02 | 山东大学 | 一种二芳基吡啶衍生物及其制备方法与应用 |
CN106831605A (zh) * | 2017-02-28 | 2017-06-13 | 山东大学 | 一种取代二芳基嘧啶类衍生物及其制备方法与应用 |
CN106866699A (zh) * | 2017-03-29 | 2017-06-20 | 山东大学 | 一种二芳基噻吩并嘧啶类hiv‑1逆转录酶抑制剂及其制备方法和应用 |
CN107778255A (zh) * | 2017-11-16 | 2018-03-09 | 山东大学 | 一种二芳基嘧啶类hiv‑1逆转录酶抑制剂及其制备方法和应用 |
CN108440559A (zh) * | 2018-04-12 | 2018-08-24 | 山东大学 | 二芳基噻吩并嘧啶类hiv-1逆转录酶抑制剂及其制备方法和应用 |
CN109053591A (zh) * | 2018-07-04 | 2018-12-21 | 复旦大学 | 含联苯结构的二芳基嘧啶类衍生物及其制备方法和用途 |
CN109369623A (zh) * | 2018-12-14 | 2019-02-22 | 山东大学 | 一种取代1,2,3三氮唑类二芳基嘧啶衍生物及其制备方法与应用 |
CN111675661A (zh) * | 2020-06-28 | 2020-09-18 | 山东大学 | 一种含有反式双键的二芳基嘧啶类hiv-1逆转录酶抑制剂及其制备方法和应用 |
CN111675694A (zh) * | 2020-06-28 | 2020-09-18 | 山东大学 | 一种含肟基团的二芳基嘧啶类hiv-1逆转录酶抑制剂及其制备方法与应用 |
CN112028836A (zh) * | 2020-09-09 | 2020-12-04 | 山东大学 | 一种含有六元氮杂环的二芳基嘧啶类衍生物及其制备方法与应用 |
CN113105394A (zh) * | 2021-03-08 | 2021-07-13 | 复旦大学 | 一种含芳杂环结构的联苯二芳基嘧啶类衍生物及其制备方法和应用 |
CN113461666A (zh) * | 2021-05-06 | 2021-10-01 | 复旦大学 | 含芳杂环结构的联苯二芳基甲基嘧啶衍生物及其制备方法 |
-
2022
- 2022-09-21 CN CN202211149680.4A patent/CN115490642A/zh active Pending
Patent Citations (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1541215A (zh) * | 2001-08-13 | 2004-10-27 | ղɭҩҵ����˾ | 抑制hiv的嘧啶衍生物 |
CN102151270A (zh) * | 2003-02-07 | 2011-08-17 | 詹森药业有限公司 | 预防hiv感染的嘧啶衍生物 |
CN103483272A (zh) * | 2013-09-29 | 2014-01-01 | 山东大学 | 间二芳烃-多取代嘧啶类衍生物及其制备方法与应用 |
CN104876860A (zh) * | 2015-05-07 | 2015-09-02 | 山东大学 | 一种二芳基吡啶衍生物及其制备方法与应用 |
CN106831605A (zh) * | 2017-02-28 | 2017-06-13 | 山东大学 | 一种取代二芳基嘧啶类衍生物及其制备方法与应用 |
CN106866699A (zh) * | 2017-03-29 | 2017-06-20 | 山东大学 | 一种二芳基噻吩并嘧啶类hiv‑1逆转录酶抑制剂及其制备方法和应用 |
CN107778255A (zh) * | 2017-11-16 | 2018-03-09 | 山东大学 | 一种二芳基嘧啶类hiv‑1逆转录酶抑制剂及其制备方法和应用 |
CN108440559A (zh) * | 2018-04-12 | 2018-08-24 | 山东大学 | 二芳基噻吩并嘧啶类hiv-1逆转录酶抑制剂及其制备方法和应用 |
CN109053591A (zh) * | 2018-07-04 | 2018-12-21 | 复旦大学 | 含联苯结构的二芳基嘧啶类衍生物及其制备方法和用途 |
CN109369623A (zh) * | 2018-12-14 | 2019-02-22 | 山东大学 | 一种取代1,2,3三氮唑类二芳基嘧啶衍生物及其制备方法与应用 |
CN111675661A (zh) * | 2020-06-28 | 2020-09-18 | 山东大学 | 一种含有反式双键的二芳基嘧啶类hiv-1逆转录酶抑制剂及其制备方法和应用 |
CN111675694A (zh) * | 2020-06-28 | 2020-09-18 | 山东大学 | 一种含肟基团的二芳基嘧啶类hiv-1逆转录酶抑制剂及其制备方法与应用 |
CN112028836A (zh) * | 2020-09-09 | 2020-12-04 | 山东大学 | 一种含有六元氮杂环的二芳基嘧啶类衍生物及其制备方法与应用 |
CN113105394A (zh) * | 2021-03-08 | 2021-07-13 | 复旦大学 | 一种含芳杂环结构的联苯二芳基嘧啶类衍生物及其制备方法和应用 |
CN113461666A (zh) * | 2021-05-06 | 2021-10-01 | 复旦大学 | 含芳杂环结构的联苯二芳基甲基嘧啶衍生物及其制备方法 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7312330B2 (en) | Bicycloheteroarylamine compounds as ion channel ligands and uses thereof | |
CN104530078B (zh) | 一种噻吩并[3,2‑d]嘧啶衍生物及其制备方法与应用 | |
CN106831605B (zh) | 一种取代二芳基嘧啶类衍生物及其制备方法与应用 | |
CN107778255B (zh) | 一种二芳基嘧啶类hiv-1逆转录酶抑制剂及其制备方法和应用 | |
KR101528946B1 (ko) | 4-피리미딘설파미드 유도체 | |
Zeng et al. | Hybrid diarylbenzopyrimidine non-nucleoside reverse transcriptase inhibitors as promising new leads for improved anti-HIV-1 chemotherapy | |
Liang et al. | Synthesis and anti-HIV activity of 2-naphthyl substituted DAPY analogues as non-nucleoside reverse transcriptase inhibitors | |
CN112920208B (zh) | 一种含硼酸的吲哚芳基砜类衍生物及其制备方法与应用 | |
EP1542978B1 (en) | Novel bio-active molecules | |
CN108218890A (zh) | 一种五元非芳环并嘧啶类hiv-1逆转录酶抑制剂及其制备方法和应用 | |
Wang et al. | Discovery of nitropyridine derivatives as potent HIV-1 non-nucleoside reverse transcriptase inhibitors via a structure-based core refining approach | |
Jin et al. | Design of the naphthyl-diarylpyrimidines as potent non-nucleoside reverse transcriptase inhibitors (NNRTIs) via structure-based extension into the entrance channel | |
CN111675661B (zh) | 一种含有反式双键的二芳基嘧啶类hiv-1逆转录酶抑制剂及其制备方法和应用 | |
JPH03127790A (ja) | N―(1h―テトラゾール―5―イル)―2―アニリノ―5―ピリミジンカルボキシアミド類及びその合成中間体 | |
CN108440559B (zh) | 二芳基噻吩并嘧啶类hiv-1逆转录酶抑制剂及其制备方法和应用 | |
Liu et al. | Design, synthesis and anti-HIV evaluation of novel diarylpyridine derivatives as potent HIV-1 NNRTIs | |
CN112375069B (zh) | 一种4-脲基嘧啶类化合物及其用途 | |
CN109369623B (zh) | 一种取代1,2,3三氮唑类二芳基嘧啶衍生物及其制备方法与应用 | |
Lu et al. | The discovery of novel diarylpyri (mi) dine derivatives with high level activity against a wide variety of HIV-1 strains as well as against HIV-2 | |
CN104876860B (zh) | 一种二芳基吡啶衍生物及其制备方法与应用 | |
CN108218896B (zh) | 一种噻唑并嘧啶类hiv-1逆转录酶抑制剂及其制备方法和应用 | |
CN115490642A (zh) | 一种含醚键的二芳基嘧啶类化合物及其制备方法与应用 | |
CN108586482A (zh) | 一种含三氮唑环的二芳基嘧啶类hiv-1抑制剂及其制备方法和应用 | |
JPS6222771A (ja) | 5−置換−6−アミノピリミジン誘導体、組成物および使用 | |
CN108409734A (zh) | 吡啶并嘧啶类hiv-1逆转录酶抑制剂及其制备方法和应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |